Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase

NCT07091747 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

61

Enrollment

OTHER

Sponsor class

Conditions

Alzheimer Disease (AD)

Interventions

OTHER: Cannabis 50 mg of CBD and 5 mg of THC

Sponsor

Federal University of Latin American Integration

Collaborators

[object Object]